2.9K(top 0.1%)
papers
111.9K(top 0.1%)
citations
137(top 0.1%)
h-index
267(top 0.1%)
g-index
3.0K
all documents
117.7K
doc citations
7.3K
citing journals

Top Articles

#TitleJournalYearCitations
1Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine20156,773
2A cell cycle regulator potentially involved in genesis of many tumor typesScience19942,664
3International uniform response criteria for multiple myelomaLeukemia20062,332
4The management of respiratory motion in radiation oncology report of AAPM Task Group 76a)Medical Physics20061,829
5Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine20171,752
6Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyLancet Oncology, The20121,182
7Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyNew England Journal of Medicine20161,140
8Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialLancet Oncology, The20151,093
9Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialLancet Oncology, The20181,089
10Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncology, The20111,028
11Cancer-associated cachexiaNature Reviews Disease Primers2018908
12Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine2005892
13Software for molecular docking: a reviewBiophysical Reviews2017880
14Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research2009872
15Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia2008787
16Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal CanalJAMA - Journal of the American Medical Association2008743
17Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialLancet, The2016724
18Localization of an ataxia-telangiectasia gene to chromosome 11q22–23Nature1988677
19Enzymatic Activity Associated with Class II HDACs Is Dependent on a Multiprotein Complex Containing HDAC3 and SMRT/N-CoRMolecular Cell2002663
20Muscle Wasting Is Associated With Mortality in Patients With CirrhosisClinical Gastroenterology and Hepatology2012659
21Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyEuropean Urology2017638
22Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology ConsortiumInternational Journal of Radiation Oncology Biology Physics2007625
23Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood2015586
24Obinutuzumab for the First-Line Treatment of Follicular LymphomaNew England Journal of Medicine2017575
25Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyLancet Oncology, The2016533
26Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology2010498
27Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/CisplatinJournal of Clinical Oncology2012480
28Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic valueLiver Transplantation2012460
29Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumourNature Genetics1994454
30Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2017451
31A convolution method of calculating dose for 15-MV x raysMedical Physics1985450
32Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialLancet Oncology, The2014446
33Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJournal of Clinical Oncology2022446
34AP Endonuclease-Independent DNA Base Excision Repair in Human CellsMolecular Cell2004434
35Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJournal of Clinical Oncology2018431
36Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialLancet Oncology, The2017428
37Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung CancerJournal of Clinical Oncology2005415
38Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary resultsSeminars in Oncology1998399
39Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastasesAnnals of Oncology2018388
40Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1Nature2005382
41Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma FoundationThe Hematology Journal2003374
42Mitotic Transcription Repression in Vivo in the Absence of Nucleosomal Chromatin CondensationJournal of Cell Biology2000372
43Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosisJournal of Cachexia, Sarcopenia and Muscle2016372
44Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.Journal of Clinical Oncology1996359
45The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix1999359
46Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12Journal of Clinical Oncology2014358
47Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancerAnnals of Oncology2004351
48Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaBlood2016347
49The relationship between waiting time for radiotherapy and clinical outcomes: A systematic review of the literatureRadiotherapy and Oncology2008334
50Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung CancerJournal of Clinical Oncology2021329